File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1136/gutjnl-2014-307237
- Scopus: eid_2-s2.0-84923060517
- WOS: WOS:000350800100022
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study
Title | Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study |
---|---|
Authors | |
Issue Date | 2015 |
Citation | Gut, 2015, v. 64 n. 4, p. 667-672 How to Cite? |
Abstract | BACKGROUND AND OBJECTIVE: The off-treatment durability of nucleos(t)ide analogue therapy in Asian hepatitis B e antigen (HBeAg) negative chronic hepatitis B (CHB) and the role of hepatitis B surface antigen (HBsAg) levels in predicting off-treatment durability has not been well investigated. METHODS: Following Asia-Pacific Association for the Study of the Liver guidelines, entecavir was stopped in Asian HBeAg negative patients treated for >/=2 years with undetectable HBV DNA levels on >/=3 separate occasions 6 months apart before treatment cessation. HBsAg and HBV DNA levels were prospectively monitored every 6-12 weeks for 48 weeks. Entecavir was restarted if there was virologic relapse (defined as HBV DNA >2000 IU/mL). RESULT: 184 patients (mean age 53.9 years, 67.9% male) were recruited. The cumulative rate of virologic relapse at 24 and 48 weeks was 74.2% and 91.4%, respectively. The median HBV DNA level at virologic relapse was 11 000 (range 2115 to >1.98x108) IU/mL. 42 (25.8%) patients had elevated alanine aminotransferase (median level 97 U/L, range 37-1058 U/L) during virologic relapse. Mean rate of off-treatment HBsAg decline was 0.018 (+/-0.456) log IU/mL/year. No patients cleared HBsAg. There was no correlation between off-treatment serial HBsAg and HBV DNA levels (r=-0.026, p=0.541). HBsAg levels at the time of entecavir commencement, entecavir cessation and the subsequent rate of HBsAg reduction were not associated with virologic relapse (all p>0.05). CONCLUSIONS: Entecavir cessation in Asian HBeAg negative CHB resulted in high rates of virologic relapse, suggesting nucleos(t)ide analogue therapy should be continued indefinitely until the recognised treatment endpoint of HBsAg seroclearance. |
Persistent Identifier | http://hdl.handle.net/10722/198045 |
ISSN | 2023 Impact Factor: 23.0 2023 SCImago Journal Rankings: 8.052 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seto, WKW | en_US |
dc.contributor.author | Hui, AJ | en_US |
dc.contributor.author | Wong, VW | en_US |
dc.contributor.author | Wong, GL | en_US |
dc.contributor.author | Liu, KS | en_US |
dc.contributor.author | Lai, CL | en_US |
dc.contributor.author | Yuen, RMF | en_US |
dc.contributor.author | Chan, HL | en_US |
dc.date.accessioned | 2014-06-25T02:42:08Z | - |
dc.date.available | 2014-06-25T02:42:08Z | - |
dc.date.issued | 2015 | en_US |
dc.identifier.citation | Gut, 2015, v. 64 n. 4, p. 667-672 | en_US |
dc.identifier.issn | 0017-5749 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/198045 | - |
dc.description.abstract | BACKGROUND AND OBJECTIVE: The off-treatment durability of nucleos(t)ide analogue therapy in Asian hepatitis B e antigen (HBeAg) negative chronic hepatitis B (CHB) and the role of hepatitis B surface antigen (HBsAg) levels in predicting off-treatment durability has not been well investigated. METHODS: Following Asia-Pacific Association for the Study of the Liver guidelines, entecavir was stopped in Asian HBeAg negative patients treated for >/=2 years with undetectable HBV DNA levels on >/=3 separate occasions 6 months apart before treatment cessation. HBsAg and HBV DNA levels were prospectively monitored every 6-12 weeks for 48 weeks. Entecavir was restarted if there was virologic relapse (defined as HBV DNA >2000 IU/mL). RESULT: 184 patients (mean age 53.9 years, 67.9% male) were recruited. The cumulative rate of virologic relapse at 24 and 48 weeks was 74.2% and 91.4%, respectively. The median HBV DNA level at virologic relapse was 11 000 (range 2115 to >1.98x108) IU/mL. 42 (25.8%) patients had elevated alanine aminotransferase (median level 97 U/L, range 37-1058 U/L) during virologic relapse. Mean rate of off-treatment HBsAg decline was 0.018 (+/-0.456) log IU/mL/year. No patients cleared HBsAg. There was no correlation between off-treatment serial HBsAg and HBV DNA levels (r=-0.026, p=0.541). HBsAg levels at the time of entecavir commencement, entecavir cessation and the subsequent rate of HBsAg reduction were not associated with virologic relapse (all p>0.05). CONCLUSIONS: Entecavir cessation in Asian HBeAg negative CHB resulted in high rates of virologic relapse, suggesting nucleos(t)ide analogue therapy should be continued indefinitely until the recognised treatment endpoint of HBsAg seroclearance. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Gut | en_US |
dc.title | Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study | en_US |
dc.type | Article | en_US |
dc.identifier.email | Seto, WKW: wkseto2@hku.hk | en_US |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | en_US |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | en_US |
dc.identifier.authority | Seto, WKW=rp01659 | en_US |
dc.identifier.authority | Yuen, RMF=rp00479 | en_US |
dc.identifier.doi | 10.1136/gutjnl-2014-307237 | en_US |
dc.identifier.scopus | eid_2-s2.0-84923060517 | - |
dc.identifier.hkuros | 229433 | en_US |
dc.identifier.isi | WOS:000350800100022 | - |
dc.identifier.issnl | 0017-5749 | - |